Poly(adenosine diphosphate-ribose) polymerase inhibition as maintenance treatment for SCLC: the search must continue
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester,Issue Date
2021
Metadata
Show full item recordAbstract
NoneCitation
Huddar P, Califano R. Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue. Journal of Thoracic Oncology. 2021 Aug;16(8):1236–8.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2021.05.016PubMed ID
34304849Additional Links
https://dx.doi.org/10.1016/j.jtho.2021.05.016Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2021.05.016
Scopus Count
Collections
Related articles
- Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
- Authors: Guo MZ, Marrone KA, Spira A, Scott SC
- Issue date: 2021 Nov-Dec 01
- A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
- Authors: Li Y, Liu CF, Rao GW
- Issue date: 2021
- [PARP (poly(ADP-ribose) polymerase) family].
- Authors: Saito H, Miki Y
- Issue date: 2012 Nov
- Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
- Authors: Tomao F, Santangelo G, Musacchio L, Di Donato V, Fischetti M, Giancotti A, Perniola G, Petrella MC, Monti M, Palaia I, Muzii L, Benedetti Panici P
- Issue date: 2020 Jun
- Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
- Authors: Markman M
- Issue date: 2018 Jan-Dec